Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients

被引：10

作者：

Calcagno, Andrea ^{[1
]}

D'Avolio, Antonio ^{[1
]}

Bonora, Stefano ^{[1
]}

机构：

[1] Univ Turin, Amedeo Savoia Hosp, Dept Med Sci, Infect Dis Unit, I-10149 Turin, Italy

来源：

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | 2015年 / 11卷 / 07期

关键词：

drug-to-drug interactions; pharmacodynamic; pharmacokinetic; raltegravir; resistance; TWICE-DAILY RALTEGRAVIR; ANTIRETROVIRAL-NAIVE ADULTS; STRAND TRANSFER INHIBITORS; ATAZANAVIR DUAL THERAPY; INTEGRASE-INHIBITOR; INFECTED PATIENTS; PLUS RALTEGRAVIR; DOUBLE-BLIND; OPEN-LABEL; HIV-1-INFECTED PATIENTS;

D O I：

10.1517/17425255.2015.1056732

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Introduction: Raltegravir was the first available integrase inhibitor for treating HIV-positive patients. This review aims to provide an overview of its role in the management of HIV-1 infection, highlighting its key pharnnacokinetic and pharmacodynamic properties. Areas covered: This review covers material searched and obtained through Medline and PubMed up to April 2015. Expert opinion: Raltegravir for its tolerability, efficacy, few drug-to-drug interactions and for the amount of available data in difficult subgroups of patients is a key drug in the antiretroviral armamentarium. For its weak genetic barrier to resistance and erratic pharmacokinetic profile, it should be administered twice daily and with fully active companion antiretrovirals.

引用

页码：1167 / 1176

页数：10

共 65 条

[1]

[Anonymous], 2015, GUID US ANT AG HIV 1

[2] Pharmacokinetics of raltegravir in the semen of HIV-infected men [J].

Antoniou, Tony ;

Loutfy, Mona R. ;

Brunetta, Jason ;

Smith, Graham ;

Halpenny, Roberta ;

la Porte, Charles .

ANTIVIRAL THERAPY, 2014, 19 (06) :607-611

[3] Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks [J].

Bloch, M. ;

Tong, W. W. Y. ;

Hoy, J. ;

Baker, D. ;

Lee, F. J. ;

Richardson, R. ;

Carr, A. .

HIV MEDICINE, 2014, 15 (06) :373-380

[4]

Boyd MA, 2013, LANCET, V381, P2091, DOI 10.1016/S0140-6736(13)61164-2

[5] Effect of Low-, Moderate-, and High-Fat Meals on Raltegravir Pharmacokinetics [J].

Brainard, Diana M. ;

Friedman, Evan J. ;

Jin, Bo ;

Breidinger, Sheila A. ;

Tillan, Maria D. ;

Wenning, Larissa A. ;

Stone, Julie A. ;

Chodakewitz, Jeffrey A. ;

Wagner, John A. ;

Iwamoto, Marian .

JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (03) :422-427

[6] HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects [J].

Buzon, Maria J. ;

Massanella, Marta ;

Llibre, Josep M. ;

Esteve, Anna ;

Dahl, Viktor ;

Puertas, Maria C. ;

Gatell, Josep M. ;

Domingo, Pere ;

Paredes, Roger ;

Sharkey, Mark ;

Palmer, Sarah ;

Stevenson, Mario ;

Clotet, Bonaventura ;

Blanco, Julia ;

Martinez-Picado, Javier .

NATURE MEDICINE, 2010, 16 (04) :460-U143

[7] Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study [J].

Cahn, Pedro ;

Pozniak, Anton L. ;

Mingrone, Horacio ;

Shuldyakov, Andrey ;

Brites, Carlos ;

Andrade-Villanueva, Jaime F. ;

Richmond, Gary ;

Beltran Buendia, Carlos ;

Fourie, Jan ;

Ramgopal, Moti ;

Hagins, Debbie ;

Felizarta, Franco ;

Madruga, Jose ;

Reuter, Tania ;

Newman, Tamara ;

Small, Catherine B. ;

Lombaard, John ;

Grinsztejn, Beatriz ;

Dorey, David ;

Underwood, Mark ;

Griffith, Sandy ;

Min, Sherene .

LANCET, 2013, 382 (9893) :700-708

[8] Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-Sectional Study of HIV-Positive Patients with Normal Renal Function [J].

Calcagno, A. ;

de Requena, D. Gonzalez ;

Simiele, M. ;

D'Avolio, A. ;

Tettoni, M. C. ;

Salassa, B. ;

Orofino, G. ;

Bramato, C. ;

Libanore, V. ;

Motta, I. ;

Bigliano, P. ;

Orsucci, E. ;

Di Perri, G. ;

Bonora, S. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (04) :1840-1843

[9] Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors [J].

Calcagno, A. ;

Tettoni, M. C. ;

Simiele, M. ;

Trentini, L. ;

Montrucchio, C. ;

D'Avolio, A. ;

Di Perri, G. ;

Bonora, S. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (02) :482-484

[10] Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-Infected Patients Are Associated With Compartmental Viral Control [J].

Calcagno, Andrea ;

Simiele, Marco ;

Alberione, Maria Chiara ;

Bracchi, Margherita ;

Marinaro, Letizia ;

Ecclesia, Sara ;

Di Perri, Giovanni ;

D'Avolio, Antonio ;

Bonora, Stefano .

CLINICAL INFECTIOUS DISEASES, 2015, 60 (02) :311-317

← 1 2 3 4 5 6 7 →